Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 16;26(12):5770.
doi: 10.3390/ijms26125770.

Overview of Cellular Therapeutics Clinical Trials: Advances, Challenges, and Future Directions

Meizhai Guo  1 , Bingyi Zheng  1 , Xiaoling Zeng  1 , Xueting Wang  1 , Chi-Meng Tzeng  1
Affiliations
Review

Overview of Cellular Therapeutics Clinical Trials: Advances, Challenges, and Future Directions

Meizhai Guo et al. Int J Mol Sci. .

Abstract

Cellular therapeutics, encompassing stem cell-based regeneration and engineered immune cell platforms, have demonstrated efficacy in treating degenerative diseases, immune-related diseases, and oncology. However, low engraftment rates and limited long-term efficacy remain critical translational barriers. This review compiled clinical projects on cell therapy in China over the past five years (over 1200 patients across 172 clinical trials) to highlight its rapid development in recent years and illustrate the directions of indications for application. This review also analyzes published clinical achievements all over the world, revealing significant therapeutic improvements in degenerative disorders (40-60% improvement in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores and oncology (78% ctDNA clearance, p < 0.001)). We propose integrating traditional Chinese medicine (TCM) bioactive compounds to enhance cell viability via C-X-C motif chemokine receptor (CXCR4) upregulation and mitochondrial biogenesis. Despite mechanistic insights, translational barriers include limited TCM validation (72% lacking single-cell omics) and regulatory misalignment. Future efforts should prioritize randomized trials and standardized TCM-cell therapy protocols to bridge discovery and clinical translation.

Keywords: CAR-T; MSC; cancer; cellular therapeutics; degeneration diseases; traditional Chinese medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 2
Figure 2
Recent clinical trials of stem cell therapies in China (classified by indication). There are 34 clinical trials for degenerative disorders, 14 related to immune-mediated diseases, and 9 for other complex illnesses.
Figure 3
Figure 3
Recent clinical trials of stem cell therapies in China (classified by cell type). The most common sources are UCMSCs (35 clinical trials), BMSCs (eight clinical trials), ADMSCs (five clinical trials), HSCs (four clinical trials), EMSCs and DPMSCs (two clinical trials each), AMSCs (one clinical trial), and PMSCs (one clinical trial).
Figure 1
Figure 1
Recent clinical trials of immune cell therapies in China (classified by cell type): CAR-T account for 96 clinical trials, T cells seven clinical trials, natural killer cells (NK) two clinical trials, tumor infiltrating lymphocytes (TIL) five clinical trials, dendritic cells (DC) three clinical trials, and chimeric antigen receptor- natural killer cells (CAR-NK) two clinical trials.
Figure 4
Figure 4
Potential mechanisms of MSC-based therapy for OA.
Figure 5
Figure 5
Generation of the neoTCR product for each patient.
See this image and copyright information in PMC

References

    1. WHO Global Cancer Burden Growing, Amidst Mounting Need for Services. 2024. [(accessed on 14 May 2025)]. Available online: https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--a.... - PMC - PubMed
    1. Takahashi J. iPSC-based cell replacement therapy: From basic research to clinical application. Cytotherapy. 2025 doi: 10.1016/j.jcyt.2025.01.015. ahead-of-print . - DOI - PubMed
    1. Im G.I. Clinical updates in mesenchymal stromal cell therapy for osteoarthritis treatment. Expert. Opin. Biol. Ther. 2025;25:187–195. doi: 10.1080/14712598.2024.2446612. - DOI - PubMed
    1. Larson C., Mendez N., Reid T. Targeting tumors using nanoparticle platforms: A phase I study of a systemically administered gene therapy system. Mol. Ther. 2013;21:922–923. doi: 10.1038/mt.2013.76. - DOI - PMC - PubMed
    1. Li X., Dai H., Wang Y., Wu Z., Wang H., Qian W., Liang A., Han W. Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China. Lancet Haematol. 2022;9:e942–e954. doi: 10.1016/S2352-3026(22)00331-3. - DOI - PubMed

MeSH terms

LinkOut - more resources